November 2014 Arizona thoracic society notes

November 2014 Arizona thoracic society notes

No abstract available. Article truncated after 150 words. The November 2014 Arizona Thoracic Society meeting was held on Wednesday, November 19, 2014 at the Scottsdale Shea Hospital beginning at 6:30 PM. This was a dinner meeting with case presentations. There were about 30 in attendance representin...

Full description

Bibliographic Details
Main Author:	Robbins RA
Format:	Article
Language:	English
Published:	Arizona Thoracic Society 2014-11-01
Series:	Southwest Journal of Pulmonary and Critical Care
Subjects:	Jud Tillinghast clinician of the year adenocarcinoma in situ minimally invasive adenocarcinoma hematoma intraparencymal hemorrhage usual interstitial pneumonia pirfenidone nintedanib Marfan's syndrome
Online Access:	http://www.swjpcc.com/arizona-ats-notes/2014/11/20/november-2014-arizona-thoracic-society-notes.html

Similar Items

February 2014 Arizona Thoracic Society notes
by: Robbins RA
Published: (2014-02-01)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
by: Toby M. Maher, et al.
Published: (2019-09-01)

Idiopathic Pulmonary Fibrosis (IPF): An Overview
by: Shaney L. Barratt, et al.
Published: (2018-08-01)

Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
by: Mehdi Mirsaeidi, et al.
Published: (2019-10-01)

Antifibrotics in interstitial lung disease related to connective tissue diseases - a paradigm shift in treatment and outcome
by: Ana Catarina Duarte, et al.
Published: (2019-04-01)

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
by: Ida Pesonen, et al.
Published: (2018-05-01)

Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions
by: Won-Il Choi
Published: (2021-03-01)

Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis
by: Cui, S., et al.
Published: (2022)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
by: John N. Shumar, et al.
Published: (2021-05-01)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)

Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective
by: Carlo Albera, et al.
Published: (2021-09-01)

September 2015 Arizona thoracic society notes
by: Robbins RA
Published: (2015-09-01)

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
by: Sebastiano Emanuele Torrisi, et al.
Published: (2019-11-01)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
by: Gareth Hughes, et al.
Published: (2016-09-01)

Idiopathic pulmonary fibrosis: pathogenesis, progression, treatments, and future prospects
by: Ouchi, Hideyasu
Published: (2019)

Efficacy and tolerability of antifibrotic agents in idiopathic pulmonary fibrosis: An experience from Turkey
by: Onur Turan, et al.
Published: (2021-01-01)

Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives
by: Moua T, et al.
Published: (2019-01-01)

Can computed tomography differentiate adenocarcinoma in situ from minimally invasive adenocarcinoma?
by: Mitsuteru Yoshida, et al.
Published: (2021-04-01)

February 2013 Arizona Thoracic Society notes
by: Robbins RA
Published: (2013-02-01)

Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives
by: Graney BA, et al.
Published: (2018-09-01)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020-10-01)

Pirfenidone vs nintedanib for treatment of idiopathic pulmonary fibrosis in clinical practice: efficacy, tolerability, and adverse effects
by: Amal A.E.-A Sadon, et al.
Published: (2020-01-01)

Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis
by: Mareike Lehmann, et al.
Published: (2018-09-01)

Lung Fibrosis after COVID-19: Treatment Prospects
by: Evgeny Bazdyrev, et al.
Published: (2021-08-01)

May 2014 Arizona thoracic society notes
by: Robbins RA
Published: (2014-06-01)

A proteomic profiling of laser‐microdissected lung adenocarcinoma cells of early lepidic‐types
by: Yasufumi Kato, et al.
Published: (2015-12-01)

March 2018 Arizona Thoracic Society notes
by: Robbins RA
Published: (2018-03-01)

Shanghai Pulmonary Hospital Experts Consensus on the Management of Ground-Glass Nodules Suspected as Lung Adenocarcinoma (Version 1)
by: Gening JIANG, et al.
Published: (2018-03-01)

Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
by: Kuo-An Chu, et al.
Published: (2020-11-01)

Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
by: Valeria Casillo, et al.
Published: (2019-09-01)

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
by: Satoshi Ikeda, et al.
Published: (2019-04-01)

Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs
by: Céline Audibert, et al.
Published: (2016-08-01)

An unusual presentation of usual-type endocervical adenocarcinoma with lobular endocervical glandular hyperplasia: A case report
by: Yasuteru Sasakura, et al.
Published: (2021-04-01)

January 2018 Arizona thoracic society notes
by: Robbins RA
Published: (2018-01-01)

Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma <it>in situ</it> (formerly bronchioloalveolar carcinoma): a patterns of failure analysis
by: Badiyan Shahed N, et al.
Published: (2013-01-01)

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
by: Paolo Cameli, et al.
Published: (2020-09-01)

Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study
by: Andrea Vianello, et al.
Published: (2020-02-01)

Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis
by: David A. Scott, et al.
Published: (2019-08-01)

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications
by: Gian Luca Erre, et al.
Published: (2021-01-01)

Current Diagnosis and Management of Hypersensitivity Pneumonitis
by: Paolo Maria Leone, M.D., et al.
Published: (2020-04-01)